Trending

Clovis

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. Approval in metastatic

X

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

https://pharmaphorum.com/news/eu-regulators-approve-astrazenecas-lynparza-in-pancreatic-cancer/

AZ/Merck & Co take on Clovis as FDA approves prostate cancer drug

AZ/Merck & Co take on Clovis as FDA approves prostate cancer drug

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator

X

AZ/Merck & Co take on Clovis as FDA approves prostate cancer drug

https://pharmaphorum.com/news/az-merck-cos-lynparza/

Clovis steals march on AZ with PARP prostate approval

Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP

X

Clovis steals march on AZ with PARP prostate approval

https://pharmaphorum.com/news/clovis-steals-march-on-az-with-parp-prostate-approval/

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the

X

AZ and MSD’s Lynparza gets fast prostate cancer FDA review

https://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate

X

Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca

https://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/

New price gets Clovis’ PARP inhibitor on the CDF

New price gets Clovis’ PARP inhibitor on the CDF

NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to

X

New price gets Clovis’ PARP inhibitor on the CDF

https://pharmaphorum.com/news/new-price-gets-clovis-parp-inhibitor-on-the-cdf/

ESMO 2019 roundup

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma

X

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

Clovis Oncology has become the latest pharma to invest in radiopharmaceuticals, signing a licensing and collaboration deal with

X

Clovis signs radiopharmaceuticals R&D deal with German biotech 3B

https://pharmaphorum.com/news/clovis-signs-radiopharmaceuticals-rd-deal-with-german-biotech-3b/

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

Clovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies

X

Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancer

https://pharmaphorum.com/news/clovis-rubraca/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com